<DOC>
	<DOCNO>NCT01615601</DOCNO>
	<brief_summary>The purpose study evaluate tolerability darunavir ( PREZISTA ) etravirine ( INTELENCE ) patient infected human immunodeficiency virus type 1 ( HIV-1 ) naïve medication patient experienced tolerability issue current prior combination antiretroviral therapy ( cART ) . The tolerability evaluate switch patient previous current combination antiretroviral therapy ( cART ) either darunavir etravirine .</brief_summary>
	<brief_title>An Observational Study Evaluate Tolerability PREZISTA INTELENCE HIV-1 Infected Patients</brief_title>
	<detailed_description>This open label ( people know identity intervention . ) , multicenter ( study conduct multiple site ) , observational study ( individual observe certain outcome ) darunavir etravirine patient infect HIV-1 naïve medication experience tolerability issue current prior combination antiretroviral therapy ( medicine use treatment HIV ) . PREZISTA indicate naïve HIV patient ( someone never use HIV drug ) treatment-experienced HIV patient INTELENCE indicate treatment-experienced patient fail prior therapy HIV-1 strain resistant multiple antiretroviral agent ( HIV-1 strain able survive exposure multiple antiretroviral agent ) , include Non-Nucleoside Reverse Transcriptase Inhibitors ( NNRTIs ) . In study patient receive either darunavir ( PREZISTA ) etravirine ( INTELENCE ) physician select optimized background agent ( antiretroviral medicine ) , permit local formulary support current Canadian Product Monograph . 90 patient participate study ( 75 Patients plan darunavir group 15 patient planned etravirine group ) . The total duration study 24 week . Safety tolerability evaluate screening ( 14 day prior Day 1 ) , baseline ( patient 's medical status treatment research do ) Day 1 , Week 4 , Week 12 Week 24 . Tolerability evaluate use HIV Symptom Distress Module ( HIV-SDM ) also refer HIV Symptom Index ( HSI ) self-completed questionnaire evaluate symptom measure presence bothersomeness side effect commonly see HIV antiretroviral treatment last 4 week ( 20 question symptom patient might past four week ) . Higher score indicate presence symptom and/or great degree distress relate 20 symptom . In HIV-SDM data collect see benefit switch either darunavir etravirine .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Have document HIV1 infection Have 1 significant symptom least grade 2 toxicity Division AIDS Toxicity `` DAIDS grade scale '' current prior combination antiretroviral therapy ( cART ) regimen ( current prior cART include regimen consist 2 Nucleoside reverse transcriptase inhibitor ( NRTIs ) third agent exception darunavir etravirine ) Have stable response current cART ie , HIVplasma viral load [ number virus blood ] screen &lt; 400 copies/mL ( undetectable ) last plasma viral load prior regimen within previous 6 month &lt; 400 copies/mL ) Must resistance Primary HIV protease inhibitor medicine Has Infected HIV2 Has receive previous treatment darunavir etravirine nonHAART ( Highly Active Antiretroviral Therapy ) regimen Has prior virologic failure 2 regimen single virologic failure prior cART Has document resistance darunavir etravirine Is currently use drug contraindicate current Canadian Product Monograph darunavir etravirine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>HIV</keyword>
	<keyword>HIV-1</keyword>
	<keyword>HIV type 1</keyword>
	<keyword>Darunavir</keyword>
	<keyword>PREZISTA</keyword>
	<keyword>Etravirine</keyword>
	<keyword>INTELENCE</keyword>
	<keyword>HIV symptom Distress Module</keyword>
	<keyword>HIV-SDM</keyword>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>HIV Symptom Index ( HSI ) ,</keyword>
</DOC>